Patents by Inventor Zane Hammoud

Zane Hammoud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR
    Publication number: 20160363560
    Abstract: Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HGD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HGD), which are widely regarded as precursors of EAC.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 15, 2016
    Applicant: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Jian Zhang, Zane Hammoud
  • Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR
    Publication number: 20140148349
    Abstract: Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HGD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HGD), which are widely regarded as precursors of EAC.
    Type: Application
    Filed: January 29, 2014
    Publication date: May 29, 2014
    Applicant: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Jian Zhang, Zane Hammoud
  • Metabolite biomarkers for the detection of esophageal cancer using NMR
    Patent number: 8653006
    Abstract: Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HGD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HGD), which are widely regarded as precursors of EAC.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: February 18, 2014
    Assignee: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Jian Zhang, Zane Hammoud
  • Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR
    Publication number: 20120142542
    Abstract: Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HOD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HOD), which are widely regarded as precursors of EAC.
    Type: Application
    Filed: September 6, 2011
    Publication date: June 7, 2012
    Applicant: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Jian Zhang, Zane Hammoud
  • METABOLITE BIOMARKERS FOR THE DETECTION OF ESOPHAGEAL CANCER USING MS
    Publication number: 20120107955
    Abstract: Results of studies of nucleosides in biofluid specimens from patients with esophageal adenocarcinoma and related disorders have identified five biomarkers of the conditions: 1-methyladenosine, N2,N2-dimethylguanosine, N2-methylguanosine, cytidine and uridine. In certain embodiments, methods of measuring these biomarkers and kits for measuring these biomarkers are provided.
    Type: Application
    Filed: September 6, 2011
    Publication date: May 3, 2012
    Applicant: Purdue Research Foundation
    Inventors: M. Daniel Raftery, Danijel Djukovic, Zane Hammoud